Vertex Pharmaceuticals plans by year-end to submit part of a license application to regulators for its kidney-disease treatment, and to have the full application submitted by first half of next year.

LONDON--(BUSINESS WIRE)--Vertex Pharmaceuticals (Europe) Limited today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for the VX-445 ...

Vertex Submits Application for Priority Review and Approval of KALYDECO TM (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis -- Accelerated ...

Vertex Submits Application for Priority Review and Approval of KALYDECO TM (VX-770, ivacaftor) in the U.S. as First Potential Medicine to Target the Underlying Cause of Cystic Fibrosis -- Accelerated ...

Vertex Pharmaceuticals (Europe) and CRISPR Therapeutics (NASDAQ: CRSP) have announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has validated the Marketing Authorisation ...